194 Superiority of A Novel Surfactant, Surfaxin (Lucinactant), Over Exosurf (Colfosceril Palmitate) in Prevnting Respiratory Distress Syndrome in Very Preterm Infants: A Pivotal, Multinational, Randomized Trial

Background: Animal-derived, protein-containing surfactants perform better vs. non–protein-containing surfactants for the prevention and treatment of Respiratory Distress Syndrome (RDS). A new generation, non–animal-derived surfactant, Surfaxin, containing a peptide that mimics human SP-B, appears effective in animals and in early studies of infants with RDS.1 Our objective was to compare the efficacy and safety of Surfaxin vs. Exosurf in the prevention of RDS.